Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline

Cytotherapy
J VaqueroNeurological Cell Therapy Group from Puerta de Hierro-Majadahonda Hospital

Abstract

Cell therapy with autologous mesenchymal stromal cells (MSCs) in patients with spinal cord injury (SCI) is beginning, and the search for its better clinical application is an urgent need. We present a phase 2 clinical trial in patients with chronic SCI who received three intrathecal administrations of 100 x 106 MSCs and were followed for 10 months from the first administration. Efficacy analysis was performed on nine patients, and safety analysis was performed on 11 patients. Clinical scales, urodynamic, neurophysiological and neuroimaging studies were performed previous to treatment and at the end of the follow-up. The treatment was well-tolerated, without any adverse event related to MSC administration. Patients showed variable clinical improvement in sensitivity, motor power, spasms, spasticity, neuropathic pain, sexual function or sphincter dysfunction, regardless of the level or degree of injury, age or time elapsed from the SCI. In the course of follow-up three patients, initially classified as ASIA A, B and C, changed to ASIA B, C and D, respectively. In urodynamic studies, at the end of follow-up, 66.6% of the patients showed decrease in postmicturition residue and improvement in bladder compliance. At this time, neurop...Continue Reading

Citations

Sep 13, 2019·Current Stem Cell Research & Therapy·Jinxuan RenLina Yu
Jul 24, 2020·Neurorehabilitation and Neural Repair·Armin CurtRaphael Guzman
Aug 9, 2020·Frontiers in Cell and Developmental Biology·Matthew H ForsbergChristian M Capitini
Sep 29, 2020·Cell & Bioscience·Ling Ling LiauJia Xian Law
Aug 17, 2019·Frontiers in Immunology·Henry CaplanCharles S Cox
Aug 1, 2020·Stem Cells International·Muhammad Najib Fathi Bin HassanJia Xian Law
Jun 6, 2020·International Journal of Molecular Sciences·Kazuyoshi YamazakiKiyohiro Houkin
Jan 19, 2021·Stem Cells International·Meichen LiuJinlan Jiang
Mar 13, 2021·World Journal of Stem Cells·Pavan S UpadhyayulaJoseph D Ciacci
Mar 23, 2021·Experimental Neurology·Jonathon Chon Teng ChioMichael G Fehlings
Jun 3, 2021·International Journal of Molecular Sciences·Pablo BonillaVictoria Moreno-Manzano
Jul 25, 2021·International Journal of Molecular Sciences·Hidenori Suzuki, Takashi Sakai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.